跳至主要内容
临床试验/NCT03338387
NCT03338387Enrolling By Invitation2 期

Acipimox Administration Together With Short-Term Exercise Exerts A Co-Feedback of Growth Hormone, Pancreatic Polypeptide, Peptide YY and Leptin on Ghrelin in Young Bulimic Czech Women: A Randomized Study

Charles University, Czech Republic0 个研究点目标入组 24 人开始时间: 2003年5月6日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
Enrolling By Invitation
发起方
入组人数
24
主要终点
Changes in plasma growth hormone levels

研究概览

简要总结

This study evaluates the addition of Acipimox or placebo to exercise on growth hormone release and ghrelin secretion in bulimic patients and in healthy women. Two groups of participants will receive Acipimox together with exercise versus identical placebo with exercise.

详细描述

Acipimox and exercise each increase growth hormone release, but they do so by different mechanisms.

Acipimox is an anti-lipolytic drug and increases growth hormone release by decreasing free fatty acids levels and that Acipimox may exert to a negative feedback of growth hormone on ghrelin.

Physical exercise is a potent physiological stimulus for growth hormone release. As ghrelin has a stimulatory effect on growth hormone secretion, growth hormone may inhibit circulating ghrelin levels via a feedback loop. Growth hormone stimulates lipolysis and resultant free fatty acids may suppress ghrelin secretion.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Participant)

入排标准

年龄范围
18 Years 至 30 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Patients with a diagnosis of bulimia nervosa
  • Body mass index (BMI) between 18 and 23 kg/m2

排除标准

  • History of heart disease
  • History of bleeding disorders
  • Subjects with diabetes type 1 or 2, hypo- or hyperthyroidism
  • Subjects with hepatogastroenteric disease
  • Pregnant, trying to become pregnant or breast feeding
  • Patients with other psychiatric diseases

研究组 & 干预措施

Acipimox

Experimental

Other Names: Olbetam

干预措施: Acipimox (Drug)

Placebo

Placebo Comparator

Other Names:

Placebo (for Olbetam)

干预措施: Placebo (Drug)

结局指标

主要结局

Changes in plasma growth hormone levels

时间窗: baseline and over a total 2 weeks

Plasma growth hormone (mIU/L) levels will be measured by a commercial RIA kit in the morning and after exercise alone or together with Acipimox administration over a total of 2 weeks.

次要结局

  • Changes in extracellular adipose tissue glycerol levels(baseline and over a total 2 weeks)

研究者

发起方
Charles University, Czech Republic
申办方类型
Other
责任方
Principal Investigator
主要研究者

Kvido Smitka

M.D., Ph.D.

Charles University, Czech Republic

相似试验